← Leaderboards
Wen-Hann Tan
Boston Children'S Hospital
$3,576,101
Attributed
$3,598,776
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2007–24$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
FDA$3,521,587 · 2
NIH$77,189 · 4
By mechanism
R01$3,521,587 · 2
R13$45,350 · 2
M01$31,839 · 2
Top collaborators
- Bianca Russell2 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Heather Elisa Olson$1,599,260
- Richard I. Gregory$15,975,785
Others in their field
Top investigators on “Grant”
- David R. Weir · University Of Michigan At Ann Arbor$373,949,788
- David Heimbrook · Leidos Biomedical Research, Inc.$341,196,902
- Eric S Lander · Whitehead Institute For Biomedical Res$323,181,457
- Jeffrey P Krischer · University Of South Florida$258,583,867
- Lawrence Corey · Fred Hutchinson Cancer Center$253,286,867
- Barton F Haynes · Duke University$243,251,908
Research focus
GrantUnited States National Institutes Of HealthResearch PersonnelClinical TrialsChildMedicalNatural HistoryResourcesQuality Of LifeCollaborationsAffectBehavior DisordersAttention Deficit Hyperactivity DisorderBiologicalAdultCommunitiesClinical ManagementAnxietyCaringChronicClinical CareAutism Spectrum DisorderChild DevelopmentBohring Syndrome
Grant awards (10)
2024 ASXL-Related Disorders Scientific Conference and Family Meeting$30,350
R13 · FY2024 · HD
ASXL-Related Disorders Scientific Conference and Family Meeting$15,000
R13 · FY2021 · HD
A Prospective Natural History Study of Angelman Syndrome: A Fresh Approach to a 10-year Longitudinal Study to Facilitate Development of Novel Therapeutic Products$1,999,988
R01 · FY2017 · FD · contact PI
A Phase II Trial of Levodopa in Angelman Syndrome$359,958
R01 · FY2013 · FD · contact PI
A Phase II Trial of Levodopa in Angelman Syndrome$359,978
R01 · FY2012 · FD · contact PI
A Phase II Trial of Levodopa in Angelman Syndrome$81,720
R01 · FY2012 · FD · contact PI
A Phase II Trial of Levodopa in Angelman Syndrome$359,971
R01 · FY2011 · FD · contact PI
A Phase II Trial of Levodopa in Angelman Syndrome$359,972
R01 · FY2010 · FD · contact PI
A THERAPEUTIC TRIAL FOR ANGELMAN SYNDROME$17,367
M01 · FY2007 · RR · contact PI
ANGELMAN SYNDROME NATURAL HISTORY STUDY$14,472
M01 · FY2007 · RR · contact PI